Kala-azar disease in a 5- month- old male, a case report and review of the literature
Keywords:
Kala azar, Infant, diagnosis, Amphotericin B LiposomalAbstract
Abstract:
Background: Kala azar is a chronic parasitic disease which is prevalent in children such as adults, however, the number of in detail reports about the clinical manifestations, diagnostic methods and the treatment options in small babies are very limited. In this study, an under 6- month- old male and his characteristics have been described.
Case presentation: A five month and 6 days male has admitted to the pediatric ward, because of 12 days’ fever, anorexia, weight loss and weakness. His physical examination findings included malaise and splenomegaly. Remarkable results in his laboratory tests have contained pancytopenia, negative results of all the performed related cultures and serologic tests. The diagnosis has been made by observing the bone marrow smear which included lots of Leishman body as extracellular and intracellular parasites within macrophages. He has responded to daily 3mg/kg Amphotericin B Liposomal for 7 doses as cumulative doses of 21mg/kg without occurring any adverse reactions or recurrence.
Conclusion: It sounds that the clinical presentation, diagnosis and treatment protocols for Kala azar disease in infants should be more studied and reported because of the several challenges this age group of children confronted to, such as different combinations of clinical presentations, protocols.
Downloads
Published
Issue
Section
Categories
License
Copyright (c) 2026 Copyright © 2025 by the Author(s). Published by Neo-ART Excellence Hub Pvt. Ltd. This article is distributed under the Creative Commons Attribution 4.0 License (CC BY 4.0). Authors retain copyright and grant the publisher the right to publish and distribute the work. https://creativecommons.org/licenses/by/4.0/

This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles published in the Journal of Clinical and Advanced Medicine (JCAM) are licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0).
This license allows anyone to share (copy and redistribute the material in any medium or format) and adapt (remix, transform, and build upon the material) for any purpose, even commercially, as long as appropriate credit is given to the original author(s) and the source.
License link: https://creativecommons.org/licenses/by/4.0/